Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited announced the issuance of 4,339,509 performance rights as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially strengthening Immutep’s position in the competitive biotechnology market.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments for cancer and autoimmune diseases. The company is known for its innovative approach in leveraging the immune system to treat these conditions, aiming to improve patient outcomes and expand its market presence in the healthcare sector.
Average Trading Volume: 2,176,193
Technical Sentiment Signal: Hold
Current Market Cap: A$448.9M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.